Athira Pharma Current Ratio vs. Shares Owned By Institutions

ATHA Stock  USD 0.66  0.01  1.54%   
Based on the key profitability measurements obtained from Athira Pharma's financial statements, Athira Pharma may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Athira Pharma's ability to earn profits and add value for shareholders.
 
Current Ratio  
First Reported
2010-12-31
Previous Quarter
5.36508322
Current Value
5.1
Quarterly Volatility
10.57099085
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, Athira Pharma's PTB Ratio is projected to increase based on the last few years of reporting. The current year's PB Ratio is expected to grow to 0.75, whereas Book Value Per Share is forecasted to decline to 3.17.
For Athira Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Athira Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Athira Pharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Athira Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Athira Pharma over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Athira Pharma. If investors know Athira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Athira Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.84)
Return On Assets
(0.48)
Return On Equity
(0.85)
The market value of Athira Pharma is measured differently than its book value, which is the value of Athira that is recorded on the company's balance sheet. Investors also form their own opinion of Athira Pharma's value that differs from its market value or its book value, called intrinsic value, which is Athira Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Athira Pharma's market value can be influenced by many factors that don't directly affect Athira Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Athira Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Athira Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Athira Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Athira Pharma Shares Owned By Institutions vs. Current Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Athira Pharma's current stock value. Our valuation model uses many indicators to compare Athira Pharma value to that of its competitors to determine the firm's financial worth.
Athira Pharma is rated third in current ratio category among its peers. It also is rated third in shares owned by institutions category among its peers producing about  2.35  of Shares Owned By Institutions per Current Ratio. At present, Athira Pharma's Current Ratio is projected to slightly grow based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Athira Pharma's earnings, one of the primary drivers of an investment's value.

Athira Shares Owned By Institutions vs. Current Ratio

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Athira Pharma

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
26.40 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Athira Pharma

Shares Held by Institutions

 = 

Funds and Banks

+

Firms

 = 
62.13 %
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.

Athira Shares Owned By Institutions Comparison

Athira Pharma is currently under evaluation in shares owned by institutions category among its peers.

Athira Pharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Athira Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Athira Pharma will eventually generate negative long term returns. The profitability progress is the general direction of Athira Pharma's change in net profit over the period of time. It can combine multiple indicators of Athira Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-349 K-366.4 K
Net Interest IncomeM2.1 M
Interest IncomeM2.1 M
Operating Income-125.5 M-119.2 M
Net Loss-117.7 M-111.8 M
Income Before Tax-117.7 M-111.8 M
Total Other Income Expense Net7.8 M4.7 M
Net Loss-86.1 M-81.8 M
Net Loss-117.7 M-111.8 M
Income Tax Expense-1.6 M-1.7 M
Non Operating Income Net Other3.7 M3.9 M
Change To Netincome12.2 M12.8 M
Net Loss(3.10)(2.94)
Income Quality 0.86  0.96 
Net Income Per E B T 0.82  0.75 

Athira Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Athira Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Athira Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Athira Pharma's important profitability drivers and their relationship over time.

Use Athira Pharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Athira Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Athira Pharma will appreciate offsetting losses from the drop in the long position's value.

Athira Pharma Pair Trading

Athira Pharma Pair Trading Analysis

The ability to find closely correlated positions to Athira Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Athira Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Athira Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Athira Pharma to buy it.
The correlation of Athira Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Athira Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Athira Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Athira Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Athira Pharma position

In addition to having Athira Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Money Funds Thematic Idea Now

Money Funds
Money Funds Theme
Funds or Etfs that invest most if their asset in companies from financial sector such as commercial banks, insurance companies, investment funds, and real estate. The Money Funds theme has 34 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Money Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Athira Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Athira Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Athira Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Athira Pharma Stock:
Check out Trending Equities.
For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
To fully project Athira Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Athira Pharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Athira Pharma's income statement, its balance sheet, and the statement of cash flows.
Potential Athira Pharma investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Athira Pharma investors may work on each financial statement separately, they are all related. The changes in Athira Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Athira Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.